PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors
暂无分享,去创建一个
Z. Modrušan | T. Januario | R. Yauch | B. Haley | B. Alicke | S. Gould | Xiao-feng Ye | Russell Bainer | Tunde Smith | Z. Modrusan
[1] A. Warth,et al. SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens. , 2017, Annals of diagnostic pathology.
[2] P. Park,et al. ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice , 2016, Nature Genetics.
[3] K. Helin,et al. Maintaining cell identity: PRC2-mediated regulation of transcription and cancer , 2016, Nature Reviews Cancer.
[4] G. Bunt,et al. Cathepsin B launches an apoptotic exit effort upon cell death-associated disruption of lysosomes , 2016, Cell Death Discovery.
[5] R. Copeland,et al. PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease. , 2016, Biochemistry.
[6] J. Trent,et al. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type , 2015, The Journal of pathology.
[7] Thomas P. Howard,et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2 , 2015, Nature Medicine.
[8] N. Girard,et al. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas , 2015, Nature Genetics.
[9] Biao Liu,et al. Frequent co‐inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours , 2015, Histopathology.
[10] G. Crabtree,et al. Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics , 2015, Science Advances.
[11] Benjamin G. Bitler,et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers , 2015, Nature Medicine.
[12] O. Delattre,et al. SWI/SNF chromatin remodeling and human malignancies. , 2015, Annual review of pathology.
[13] P. Trojer,et al. EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation. , 2014, Chemistry & biology.
[14] J. Biegel,et al. SWI/SNF chromatin remodeling complexes and cancer , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.
[15] W. Foulkes,et al. No small surprise – small cell carcinoma of the ovary, hypercalcaemic type, is a malignant rhabdoid tumour , 2014, The Journal of pathology.
[16] D. Reisman,et al. The silencing of the SWI/SNF subunit and anticancer gene BRM in Rhabdoid tumors , 2014, Oncotarget.
[17] N. Schultz,et al. Recurrent SMARCA4 mutations in small cell carcinoma of the ovary , 2014, Nature Genetics.
[18] R. Siebert,et al. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type , 2014, Nature Genetics.
[19] C. Roberts,et al. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers , 2014, Proceedings of the National Academy of Sciences.
[20] W. Hahn,et al. Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation , 2014, Molecular and Cellular Biology.
[21] R. Copeland,et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 , 2013, Proceedings of the National Academy of Sciences.
[22] Yan Liu,et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.
[23] D. Reisman,et al. Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy , 2011, Oncogene.
[24] S. Orkin,et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. , 2010, Cancer cell.
[25] C. Roberts,et al. Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex. , 2009, Cancer research.
[26] E. Moran,et al. Antagonistic Roles for BRM and BRG1 SWI/SNF Complexes in Differentiation , 2009, Journal of Biological Chemistry.
[27] D. Metzger,et al. Targeted knockout of BRG1 potentiates lung cancer development. , 2008, Cancer research.
[28] M. Bollen,et al. The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene silencing , 2008, Oncogene.
[29] D. Reisman,et al. The reversible epigenetic silencing of BRM: implications for clinical targeted therapy , 2007, Oncogene.
[30] Weidong Wang,et al. Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. , 2003, Cancer research.
[31] B. Emerson,et al. Transcriptional specificity of human SWI/SNF BRG1 and BRM chromatin remodeling complexes. , 2003, Molecular cell.
[32] Marcel Leist,et al. Cathepsin B Acts as a Dominant Execution Protease in Tumor Cell Apoptosis Induced by Tumor Necrosis Factor , 2001, The Journal of cell biology.
[33] A. Sands,et al. Disruption of Ini1 Leads to Peri-Implantation Lethality and Tumorigenesis in Mice , 2001, Molecular and Cellular Biology.
[34] C. Roberts,et al. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[35] Olivier Delattre,et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer , 1998, Nature.
[36] Guha,et al. Functional interactions between the hBRM/hBRG1 transcriptional activators and the pRB family of proteins , 1996, Molecular and cellular biology.
[37] C. Roberts,et al. ARID1A mutations in cancer: another epigenetic tumor suppressor? , 2013, Cancer discovery.